Your browser is no longer supported. Please, upgrade your browser.
Catabasis Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.04 Insider Own0.11% Shs Outstand20.10M Perf Week-17.34%
Market Cap55.51M Forward P/E- EPS next Y-0.64 Insider Trans0.00% Shs Float20.06M Perf Month-37.43%
Income-37.30M PEG- EPS next Q-0.18 Inst Own38.40% Short Float12.95% Perf Quarter-17.34%
Sales- P/S- EPS this Y13.40% Inst Trans-6.53% Short Ratio0.43 Perf Half Y-64.27%
Book/sh2.02 P/B1.11 EPS next Y3.00% ROA-67.60% Target Price- Perf Year-57.66%
Cash/sh1.81 P/C1.24 EPS next 5Y- ROE-76.70% 52W Range1.25 - 8.59 Perf YTD4.67%
Dividend- P/FCF- EPS past 5Y37.50% ROI- 52W High-73.92% Beta1.72
Dividend %- Quick Ratio7.20 Sales past 5Y- Gross Margin- 52W Low79.20% ATR0.22
Employees20 Current Ratio7.20 Sales Q/Q- Oper. Margin- RSI (14)31.57 Volatility8.37% 7.66%
OptionableYes Debt/Eq0.00 EPS Q/Q19.20% Profit Margin- Rel Volume0.13 Prev Close2.37
ShortableYes LT Debt/Eq0.00 EarningsMar 11 AMC Payout- Avg Volume6.08M Price2.24
Recom2.00 SMA20-21.20% SMA50-27.25% SMA200-45.99% Volume771,671 Change-5.49%
Mar-11-21Upgrade Oppenheimer Perform → Outperform $5
Nov-02-20Downgrade Wedbush Outperform → Neutral
Oct-27-20Downgrade Oppenheimer Outperform → Perform
Oct-27-20Downgrade H.C. Wainwright Buy → Neutral
Oct-01-20Initiated H.C. Wainwright Buy $24
Oct-05-17Reiterated Oppenheimer Outperform $4 → $7
Feb-02-17Downgrade Citigroup Buy → Neutral
Dec-22-16Initiated H.C. Wainwright Buy $14
Jun-08-16Reiterated Wedbush Outperform $27 → $17
Jul-20-15Initiated Wedbush Outperform $27
Jul-20-15Initiated Oppenheimer Outperform $28
Jul-20-15Initiated Citigroup Buy $21
Mar-11-21 04:10PM  
Mar-02-21 08:00AM  
Jan-29-21 10:46AM  
Dec-03-20 08:56AM  
Dec-02-20 08:38PM  
Nov-12-20 04:10PM  
Oct-28-20 07:41AM  
Oct-27-20 08:24AM  
Oct-26-20 05:00PM  
Sep-28-20 08:00AM  
Sep-23-20 08:00AM  
Sep-21-20 08:00AM  
Sep-10-20 08:51AM  
Sep-08-20 08:00AM  
Sep-03-20 08:41AM  
Sep-02-20 08:00AM  
Aug-25-20 08:38AM  
Aug-21-20 10:35AM  
Aug-10-20 04:10PM  
Aug-05-20 08:00AM  
Aug-04-20 08:00AM  
Jul-27-20 08:00AM  
Jul-15-20 08:00AM  
Jun-29-20 04:10PM  
Jun-15-20 08:16PM  
Jun-12-20 08:00AM  
May-12-20 04:10PM  
May-07-20 09:30AM  
Apr-28-20 08:00AM  
Apr-17-20 08:00AM  
Mar-27-20 03:22AM  
Mar-25-20 08:00AM  
Mar-24-20 04:00PM  
Mar-18-20 08:00AM  
Mar-14-20 09:32AM  
Mar-10-20 08:05AM  
Feb-25-20 08:00AM  
Feb-21-20 08:00AM  
Feb-03-20 04:05PM  
Jan-30-20 09:00AM  
Jan-29-20 04:01PM  
Jan-09-20 04:09PM  
Jan-08-20 08:00AM  
Dec-24-19 06:15AM  
Dec-23-19 02:15PM  
Dec-16-19 08:00AM  
Nov-25-19 06:45PM  
Nov-18-19 06:53AM  
Nov-07-19 08:05AM  
Oct-24-19 08:00AM  
Oct-19-19 09:26AM  
Oct-18-19 08:00AM  
Oct-05-19 08:00AM  
Sep-30-19 04:05PM  
Sep-27-19 08:00AM  
Sep-26-19 08:00AM  
Sep-25-19 08:00AM  
Sep-19-19 10:13AM  
Aug-20-19 10:58AM  
Aug-09-19 05:04PM  
Aug-08-19 08:05AM  
Aug-07-19 08:00AM  
Aug-06-19 08:00AM  
Jul-25-19 08:30AM  
Jul-15-19 03:08PM  
Jun-27-19 08:00AM  
Jun-21-19 09:45AM  
Jun-18-19 08:00AM  
Jun-07-19 09:24AM  
May-15-19 06:33PM  
May-14-19 08:05AM  
May-02-19 08:00AM  
Apr-30-19 08:00AM  
Apr-26-19 03:26PM  
Apr-12-19 11:34AM  
Apr-01-19 08:00AM  
Mar-26-19 12:11PM  
Mar-19-19 12:26PM  
Mar-18-19 09:02AM  
Mar-14-19 06:09PM  
Mar-13-19 08:00AM  
Mar-08-19 09:54AM  
Mar-07-19 08:57AM  
Mar-06-19 01:56PM  
Feb-28-19 08:00AM  
Feb-19-19 08:00AM  
Feb-14-19 08:00AM  
Feb-06-19 09:00AM  
Feb-05-19 04:01PM  
Jan-29-19 07:55AM  
Catabasis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. The company's lead product candidate is QLS-215, a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development for the treatment of hereditary angioedema, a rare, debilitating and potentially life-threatening disease. The company was incorporated in 2008 and is based in Boston, Massachusetts.